Latest Ratios: P/E Ratio -0.3x · EV/EBITDA N/A · ROE -56.2%. (2014–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7M | $189069 | $42259 | $51616 | $46752 | $46697 | $9117 | $7081 | $11285 | — | — |
| Enterprise Value | $5M | $-2175931 | $-647741 | $-2166384 | $-2792248 | $-52675068 | $-8444819 | $-443517 | $-2729360 | — | — |
| P/E Ratio → | -0.32 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | 0.23 | 0.06 | — | — |
| P/B Ratio | 0.23 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | -14.20 | -14.63 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 100.0% | 100.0% | -32.4% | -22.3% |
| Operating Margin | — | — | — | — | — | — | — | -24566.5% | -4210.5% | -1445.9% | -592.8% |
| Net Profit Margin | — | — | — | — | — | — | — | -24406.7% | -6991.5% | -1845.8% | -749.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -56.2% | -56.2% | -49.4% | -55.4% | -53.0% | -53.7% | -225.9% | -503.9% | -640.5% | — | — |
| ROA | -52.3% | -52.3% | -46.6% | -52.1% | -49.7% | -48.4% | -130.8% | -218.1% | -451.7% | -389.8% | -252.8% |
| ROIC | -47.3% | -47.3% | -41.8% | -47.4% | -99.5% | -7764.0% | — | — | — | — | — |
| ROCE | -59.5% | -59.5% | -52.9% | -57.8% | -51.8% | -53.2% | -205.1% | -427.1% | -385.7% | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.12 | 0.87 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.09 | -0.02 | -0.05 | -0.07 | -0.97 | -1.19 | -0.46 | -1.35 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -2443.30 | -8171.99 | -0.90 | -3.06 | -95.53 |
Net cash position: cash ($3M) exceeds total debt ($700000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.58 | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.19 |
| Quick Ratio | 13.58 | 13.58 | 20.88 | 34.23 | 25.78 | 34.83 | 3.00 | 0.76 | 1.86 | 0.02 | 0.15 |
| Cash Ratio | 13.30 | 13.30 | 20.60 | 33.85 | 25.52 | 34.64 | 2.93 | 0.70 | 1.80 | 0.01 | 0.03 |
| Asset Turnover | — | — | — | — | — | — | — | 0.01 | 0.05 | 0.19 | 0.44 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | 10.58 |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | 62.65 | 30.42 | 92.77 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $589000 | $13993 | $10042 | $9167 | $7086 | $1054 | $515 | $306 | $316 | $358 |
Binary Clinical Trial Outcome
As reported in recent financial data, NVNO trades at a price-to-book ratio of 0.24, which suggests that the market is heavily discounting the company's asset base in anticipation of potential future dilution or the binary risks associated with the ongoing SAVVE clinical trial program.
The current valuation multiple appears to reflect a significant liquidity discount compared to more mature vascular device peers. Investors should monitor whether this low P/B ratio represents a genuine value opportunity or a rational market response to the company's limited cash runway and lack of commercial revenue.
Based on historical financial statements, NVNO's ROIC has consistently remained in negative territory, reaching -13.1% in 2026Q1, which highlights the company's ongoing struggle to generate returns on invested capital while it remains in the pre-revenue, clinical-stage phase of its business lifecycle.
The persistent negative return on capital is a structural reality for a firm that has yet to commercialize its lead bioprosthetic valve technology. This trend suggests that capital is being consumed primarily for regulatory and clinical milestones rather than for generating productive, return-yielding assets.
According to the 2026Q1 balance sheet, the company maintains a current ratio of 11.89, yet this figure is misleading as it masks the rapid depletion of cash reserves required to fund the SAVVE trial and support the broader transcatheter development program through the next fiscal year.
While the high current ratio might suggest short-term solvency, the absolute cash balance of $3.065 million warrants further investigation into the company's ability to sustain operations. The lack of revenue-generating activities means that liquidity is entirely dependent on external financing, which may become increasingly expensive or dilutive.
As indicated by the reported 0.03 debt-to-equity ratio, investors should be wary of using this metric to assess financial health, as it obscures the company's extreme reliance on equity markets to fund its clinical development rather than utilizing traditional debt financing for operational growth.
The low debt-to-equity ratio is a function of the company's inability to access credit markets rather than a sign of a strong balance sheet. Analysts should instead focus on the cash-to-burn ratio, which provides a more accurate picture of the company's survival timeline and potential for future shareholder dilution.
Includes 30+ ratios · 12 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NVNO stock.
enVVeno Medical Corporation's current P/E ratio is -0.3x. This places it at the 50th percentile of its historical range.
enVVeno Medical Corporation's return on equity (ROE) is -56.2%. The historical average is -82.3%.
Based on historical data, enVVeno Medical Corporation is trading at a P/E of -0.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.